GleamWall
中文EN

BTAIQ BioXcel Therapeutics, Inc.

Pharmaceutical Preparations · OTC · SEC CIK 1720893 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY-14.5%
TTM net income YoY-39.1%
TTM EPS YoY78.3%
Revenue 3-yr CAGR-10.6%
Net income 3-yr CAGR—

Margins

Gross margin53.1%
Operating margin-6,054.7%
Net margin-9,549.9%
FCF margin-6,860.4%
EBITDA margin-6,024.4%

Returns

ROE—
ROA-259.6%
ROIC (approx.)—
Asset turnover0.03x

Leverage & solvency

Liabilities / assets500.9%
Debt / equity—
Current ratio0.21x
Interest coverage-2.61x

Cash quality & payout

Operating cash flow / net income0.72x
Accruals ratio-73.1%
Payout ratio—
Capex / revenue0.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-312024Q32024-09-30
Income statement
Revenue$182,000$206,000$256,000$98,000$120,000$168,000$366,000$214,000
Cost of revenue$22,000$283,000$32,000$11,000$107,000$14,000$832,000$1.17M
Gross profit$160,000-$77,000$224,000$87,000$13,000$154,000-$466,000-$956,000
R&D expense$3.16M$2.96M$6.70M$8.74M$10.26M$4.55M$5.90M$5.10M
SG&A expense$7.19M$7.19M$3.81M$5.38M$5.61M$5.70M$4.09M$7.68M
Operating income-$10.19M-$10.22M-$10.28M-$14.23M-$15.85M-$10.10M-$10.49M-$15.29M
Interest expense$4.26M$4.20M$4.40M$4.37M$4.22M$3.99M$4.03M$3.79M
Net income-$14.71M-$12.69M-$12.54M-$30.91M-$19.19M-$7.25M-$10.86M-$13.65M
EBITDA-$10.18M-$10.16M-$10.21M-$14.15M-$15.78M-$10.02M-$10.42M-$15.22M
EPS (basic)-0.49-0.54—-2.18-2.45-1.50—-5.15
EPS (diluted)-0.49-0.54—-2.18-2.45-1.50—-5.15
Weighted avg. shares (diluted)30.30M23.57M—14.20M7.84M4.83M—2.65M
Balance sheet
Cash & equivalents$12.84M$17.18M$28.41M$36.18M$17.43M$31.01M$29.85M$40.39M
Receivables$82,000$216,000$233,000$0$17,000—$131,000$3,000
Inventory$483,000$500,000$722,000$459,000$506,000$642,000$679,000$1.52M
Current assets$28.70M$33.91M$44.69M$44.40M$25.24M$37.78M$37.39M$47.79M
PP&E, net$99,000$117,000$175,000$249,000$324,000$399,000$475,000$552,000
Total assets$28.80M$34.02M$44.92M$44.79M$25.79M$38.57M$38.34M$48.89M
Current liabilities$137.15M$54.99M$53.93M$37.80M$33.38M$25.55M$22.23M$25.56M
Short-term debt$104.45M$22.43M$24.93M$16.82M$11.22M$5.61M$0—
Long-term debt$0$77.86M$84.66M$92.30M$97.47M$99.92M$102.51M$104.44M
Total debt$104.45M$100.29M$109.59M$109.12M$108.69M$105.53M$102.51M$104.44M
Total liabilities$144.26M$139.57M$140.38M$133.71M$133.46M$128.74M$131.44M$134.53M
Shareholders' equity-$115.46M-$105.54M-$95.46M-$88.92M-$107.67M-$90.17M-$93.10M-$85.63M
Net debt$91.61M$83.11M$81.18M$72.95M$91.25M$74.51M$72.65M$64.05M
Shares outstanding31.30M27.07M22.33M20.00M6.62M5.47M3.10M42.46M
Cash flow statement
Operating cash flow-$6.10M-$11.81M-$14.21M-$18.79M-$12.57M-$12.04M-$14.81M-$16.34M
Capital expenditure$0$0$0$0$0$0$0$0
Free cash flow-$6.10M-$11.81M-$14.21M-$18.79M-$12.57M-$12.04M-$14.81M-$16.34M
Investing cash flow$0$0$0$0$0$0$0$0
Financing cash flow$2.72M$232,000$5.65M$37.53M$137,000$13.20M$4.28M$454,000
Depreciation & amortization$18,000$58,000$74,000$75,000$75,000$76,000$77,000$77,000
Stock-based compensation$358,000$435,000$450,000$581,000$1.56M$180,000-$199,000$1.86M

Free plan shows the latest 8 periods; Pro shows all 38 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.